KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Land & Improvements (2016 - 2018)

Teva Pharmaceutical Industries filings provide 7 years of Land & Improvements readings, the most recent being $351.0 million for Q4 2018.

  • On a quarterly basis, Land & Improvements fell 10.0% to $351.0 million in Q4 2018 year-over-year; TTM through Dec 2018 was $351.0 million, a 10.0% decrease, with the full-year FY2018 number at $351.0 million, down 10.0% from a year prior.
  • Land & Improvements hit $351.0 million in Q4 2018 for Teva Pharmaceutical Industries, down from $361.0 million in the prior quarter.
  • In the past five years, Land & Improvements ranged from a high of $439.0 million in Q4 2016 to a low of $351.0 million in Q4 2018.
  • Median Land & Improvements over the past 5 years was $373.0 million (2014), compared with a mean of $379.9 million.
  • Biggest five-year swings in Land & Improvements: decreased 16.59% in 2014 and later rose 11.42% in 2016.
  • Teva Pharmaceutical Industries' Land & Improvements stood at $372.0 million in 2014, then grew by 5.91% to $394.0 million in 2015, then increased by 11.42% to $439.0 million in 2016, then dropped by 11.16% to $390.0 million in 2017, then dropped by 10.0% to $351.0 million in 2018.
  • The last three reported values for Land & Improvements were $351.0 million (Q4 2018), $361.0 million (Q3 2018), and $374.0 million (Q2 2018) per Business Quant data.